Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €0.21 EUR
Change Today -0.007 / -3.21%
Volume 282.8K
As of 11:30 AM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Joukahaisenkatu 6

Turku, 20520

Finland

Phone: 358 2274 8900

Fax: 358 2274 8910

Biotie Therapies Corp., a drug development company, focuses on the development of drugs for neurodegenerative and psychiatric disorders primarily in Finland and the United States. Its products include Selincro (nalmefene), a dual-acting opioid system modulator that reduces alcohol consumption in alcohol dependent individuals; Tozadenant (SYN115), an oral, potent and selective adenosine A2a receptor antagonist for the treatment of Parkinson’s disease that is in Phase III development; and Nepicastat (SYN117) an orally administered inhibitor for the treatment for cocaine dependence, which has completed in Phase II trial. The company’s products also comprise BTT1023, a monoclonal antibody targeting Vascular Adhesion Protein 1 in Phase II development in fibrotic conditions and received orphan drug designation for the treatment of primary sclerosing cholangitis; and SYN120, an oral, potent, dual antagonist of the 5-HT6 and 5-HT2A receptors that has completed single and multiple ascending dose Phase I clinical studies and a Phase I positron emission tomography imaging study to determine therapeutic dose for subsequent Phase II studies. Biotie Therapies Corp. is based in Turku, Finland.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BTH1V:FH €0.21 EUR -0.007

BTH1V Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BTH1V.
View Industry Companies
 

Industry Analysis

BTH1V

Industry Average

Valuation BTH1V Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.5x
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 16.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOTIE THERAPIES OYJ, please visit www.biotie.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.